Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2015 1
2016 1
2021 2
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E, Scoulica E. Maraki S, et al. Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1755-1759. doi: 10.1007/s10096-021-04197-3. Epub 2021 Feb 17. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33595756
The newly introduced beta-lactam-beta-lactamase inhibitors (BLBLIs), ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (M/V), and imipenem/relebactam (I/R) are inactive against MBLs. The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) …
The newly introduced beta-lactam-beta-lactamase inhibitors (BLBLIs), ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (M/V), an …
Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S, Mavromanolaki VE, Magkafouraki E, Moraitis P, Stafylaki D, Kasimati A, Scoulica E. Maraki S, et al. Infection. 2022 Apr;50(2):467-474. doi: 10.1007/s15010-021-01735-1. Epub 2021 Dec 2. Infection. 2022. PMID: 34854060
This study evaluated the epidemiology of carbapenemase-producing K. pneumoniae isolates collected at a Greek university hospital during 2017-2020, and their susceptibilities to ceftazidime-avibactam (CAZ/AVI), meropenem-vaborbactam (M/V), imipenem-relebactam (I/R), …
This study evaluated the epidemiology of carbapenemase-producing K. pneumoniae isolates collected at a Greek university hospital during 2017 …
In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S, Mavromanolaki VE, Stafylaki D, Scoulica E. Maraki S, et al. J Chemother. 2023 Nov;35(7):596-600. doi: 10.1080/1120009X.2023.2170906. Epub 2023 Jan 27. J Chemother. 2023. PMID: 36705145
All KPC-producing K. pneumoniae were susceptible to ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (M/V) and 97.2% of them to imipenem-relebactam (I/R). Among the MBL-producing isolates, PL and CFDC exhibited the highest activity....
All KPC-producing K. pneumoniae were susceptible to ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (M/V) and 97.2% of them …
Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity.
Maraki MI, Aggelopoulou N, Christodoulou N, Anastasiou CA, Toutouza M, Panagiotakos DB, Kavouras SA, Magkos F, Sidossis LS. Maraki MI, et al. Obesity (Silver Spring). 2011 May;19(5):968-76. doi: 10.1038/oby.2010.218. Epub 2010 Sep 30. Obesity (Silver Spring). 2011. PMID: 20885389 Free article.
For this purpose, postprandial lipemia was investigated in eight obese but otherwise healthy, sedentary men (age: 41.3 4.1 years, BMI: 36.5 1.6 kg.m(-2)), once before and again after a 10% weight loss followed by 4 weeks of weight maintenance, and was compared with that of …
For this purpose, postprandial lipemia was investigated in eight obese but otherwise healthy, sedentary men (age: 41.3 4.1 years, BMI: 36.5 …
Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.
Souli M, Karaiskos I, Galani L, Maraki S, Perivolioti E, Argyropoulou A, Charissiadou A, Zachariadou L, Tsiplakou S, Papaioannou V, Tsorlini H, Katsifa H, Baka V, Pantazi P, Paschali A, Kyratsa A, Trikka-Graphakos E, Giannopoulou P, Vogiatzakis E, Moraitou H, Papadogeorgaki H, Avgerinou H, Panagea T, Pantazatou A, Petinaki E, Stamatopoulou G, Toutouza M, Karatzoglou I, Kontopoulou K, Orfanidou M, Karantani I, Fytas P, Tzanetou K, Platsouka E, Kazila P, Chli A, Statiri N, Giamarellou H. Souli M, et al. Infect Dis (Lond). 2016 Apr;48(4):287-292. doi: 10.3109/23744235.2015.1110858. Epub 2015 Dec 4. Infect Dis (Lond). 2016. PMID: 26635179
The MICs were evaluated by Vitek 2 with the exception of ceftaroline (OXOID M.I.C. Evaluator). Vancomycin and daptomycin MICs were also evaluated by Etest. Heterogeneously vancomycin-intermediate strains (hVISA) were detected by the Etest GRD. ...
The MICs were evaluated by Vitek 2 with the exception of ceftaroline (OXOID M.I.C. Evaluator). Vancomycin and daptomycin MICs were al …